Crinecerfont Lets Kids With CAH Cut Steroid Doses Safely

Congenital adrenal hyperplasia (CAH) is a genetic disorder in which the adrenal glands cannot produce cortisol normally, triggering the pituitary to release excess ACTH. This drives overproduction of androgens, causing serious complications including abnormal growth, early puberty, and fertility problems. For decades, the only treatment was high-dose glucocorticoids (GCs) to suppress ACTH — but those doses far exceed physiologic needs and cause their own harms, including growth suppression, obesity, and metabolic dysfunction.

Crinecerfont, a CRF1 receptor antagonist, was approved in 2024 as an adjunctive therapy for classic CAH in patients aged 4 and older. By blocking the upstream signal that drives ACTH release, it reduces androgen overproduction independently of GC suppression. This creates an opportunity to lower GC doses to physiologic replacement levels — a fundamentally different treatment paradigm.

To guide clinicians through this transition, 11 expert pediatric endocrinologists convened in December 2024 and January 2025 to develop consensus recommendations. Their guidance focuses on how to reduce GC doses safely after initiating crinecerfont in children aged 4–17. Key principles include tailoring reductions to individual clinical goals, using androgen concentrations as the primary guide, and reducing doses gradually with frequent monitoring.

Critically, GC doses should never fall below the amount needed for physiologic cortisol replacement — protecting against adrenal crisis remains paramount. The target is to normalize androgen levels sufficiently to support healthy growth and appropriate bone age maturation, while eliminating the long-term toxicity of supraphysiologic steroid exposure.

These recommendations represent an important clinical milestone. As crinecerfont adoption grows, clinicians will need structured protocols for this dose-reduction process. The expert panel's framework provides that foundation, though real-world outcomes data will be needed to validate and refine these consensus-based guidelines over time.